ChemoCentryx to Hold Fourth Quarter and Full Year 2021 Financial Results Conference Call on Tuesday, March 1, 2022
Rhea-AI Summary
ChemoCentryx, based in Mountain View, California, has announced that it will release its fourth quarter and full year 2021 financial results after market close on March 1, 2022. An investor conference call will follow at 5:00 p.m. Eastern Time that same day. The call will be accessible by phone and through a webcast via the Company's website. ChemoCentryx is focused on developing therapies for inflammatory and autoimmune diseases, with TAVNEOS being their key marketed product for ANCA-associated vasculitis. For further details, visit their official site.
Positive
- Scheduled release of 2021 financial results indicates transparency to investors.
- TAVNEOS is the first oral inhibitor for ANCA-associated vasculitis, showing a strong market position.
Negative
- None.
News Market Reaction – CCXI
In the trading session that priced this news, CCXI declined 3.99%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MOUNTAIN VIEW, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's fourth quarter and full year 2021 financial results will be released after market close on Tuesday, March 1, 2022. ChemoCentryx executive management will host a conference call and webcast beginning at 5:00 p.m. Eastern Time on March 1, 2022 to discuss these results and to answer questions.
To participate by telephone, please dial (877) 303-8028 (Domestic) or (760) 536-5167 (International). The conference ID number is 3136966. A live and archived audio webcast can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com. The archived webcast will remain available on the Company's website for fourteen (14) days following the call.
About ChemoCentryx
ChemoCentryx is a biopharmaceutical company commercializing and developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. In the United States, ChemoCentryx markets TAVNEOS® (avacopan), the first approved orally-administered inhibitor of the complement 5a receptor as an adjunctive treatment for adult patients with severe active ANCA-associated vasculitis. TAVNEOS is also in late-stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 glomerulopathy (C3G). Additionally, ChemoCentryx has early-stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer. For more information about the Company visit www.chemocentryx.com.
TAVNEOS® is a registered trademark of ChemoCentryx, Inc. For more information, please see the Full Prescribing Information and Medication Guide, available at TAVNEOS.com.
Contacts
Investors:
Bill Slattery, Jr.
Vice President, Investor Relations
and Corporate Communications
650.210.2970
bslattery@chemocentryx.com
Media:
Stephanie Tomei
408.234.1279
media@chemocentryx.com
